In the BioHarmony Drug Report Database

"Preview" Icon

Tildrakizumab-asmn

Ilumya, Ilumetri (tildrakizumab) is an antibody pharmaceutical. Tildrakizumab was first approved as Ilumya on 2018-03-20. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.

 

Trade Name

 

Ilumetri
 

Common Name

 

tildrakizumab
 

ChEMBL ID

 

CHEMBL2108681
 

Indication

 

psoriasis
 

Drug Class

 

Monoclonal antibodies: humanized, interleukins as target

Image (chem structure or protein)

Tildrakizumab-asmn structure rendering